Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell

Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other equities research analysts also recently issued reports on the stock. Wells Fargo & Company lifted their price target on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Morgan Stanley set a $33.00 price target on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.67.

Kyverna Therapeutics Trading Down 7.0%

NASDAQ KYTX opened at $7.94 on Friday. The stock has a market cap of $347.77 million, a P/E ratio of -2.13 and a beta of 3.31. The company’s fifty day simple moving average is $8.36 and its 200-day simple moving average is $7.49. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $13.67.

Hedge Funds Weigh In On Kyverna Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new position in Kyverna Therapeutics in the third quarter worth $28,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Kyverna Therapeutics during the second quarter worth $37,000. Qube Research & Technologies Ltd acquired a new stake in shares of Kyverna Therapeutics during the second quarter worth $43,000. Capital Advisors Inc. OK bought a new position in shares of Kyverna Therapeutics in the 3rd quarter worth about $60,000. Finally, Rhumbline Advisers lifted its position in shares of Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after buying an additional 5,694 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.